Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...
Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress. Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates ...
Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress. At the ...
An expert discusses how comparing the durability and treatment effects of newer minimally invasive therapies to gold standard transurethral resection of the prostate (TURP) or holmium laser ...
This discussion compares subcutaneous and intravenous immunotherapy delivery, highlighting differences in clinical use, patient convenience, and overall treatment experience. This program examines the ...
Chan shares how her passion for research and desire to impact patients on a broader scale led her from academia to industry. In this episode of Pearls & Perspectives, host Amy Pearlman, MD, welcomes ...
Panelists discuss how IsoPSA’s long-term predictive performance supports safer follow-up strategies and greater confidence in risk-based management. Panelists discuss how IsoPSA’s predictive ...
Incorporating mpMRI before TURBT improves bladder cancer-specific survival in patients with suspected MIBC. The BladderPath trial aimed to reduce time to radical treatment by comparing mpMRI before ...
Adjuvant durvalumab plus tremelimumab improved DFS in resected RCC, especially in high-risk patients, with a 43% reduction in recurrence risk. The trial enrolled patients into three arms, with the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback